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adverse effects proﬁle of the medication. The most support was registered for the 
optimal scenario (halt disease progression, no adverse effects).
PND49
MIGRAINE: PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY 
CARE PATIENT POPULATION
Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa
OBJECTIVES: Migraine affects 8% to 14% of the population in Western countries. 
It affects primarily the young adult population and is responsible for many lost 
working days each year since it affects primarily the economically active sector of the 
community. The primary aim of the study was to determine the prescribing patterns 
and cost of drugs for migraine in a primary care patient population. METHODS: A 
retrospective drug utilisation consumption study was conducted. Data were obtained 
from a South African private health care group. The database consisted of all central 
nervous system medicine for 2008. RESULTS: A total of 22102 patients (71.05% 
females) received 43144 items for migraine a cost of R3622552 (average cost of 
R83.96 per item). The average age of patients was 44.90 (SD  13.83) years, with 
70.76% of patients between 30 and 59 years of age. The chi-square test was used to 
detect prescribing differences between female and male patients in different age groups 
(chi2  212.31; d.f.  6; p  0.0001). Differences were observed in prescribing to female 
and male patients. Patients were prescribed an average of 1.95 items for migraine over 
the year. The Lorenz curve was used to illustrate skewness in prescribing. Clonidine 
was the most frequently prescribed active ingredient (46.15%), followed by cyclizine 
(29.62%). The agents for the prophylaxis of migraine (clonidine, ﬂunarizine and 
pizotifen) accounted for 50.48% of prescribing frequency and 29.04% of cost. The 
selective 5HT1-receptor agonists (triptans) accounted for 18.94% of prescribing fre-
quency and 53.54% of cost. Rizatriptan was the most frequently prescribed triptan. 
CONCLUSIONS: The ﬁndings were generally in agreement with two other South 
African studies, although differences were observed. A lower prescribing rate for 
triptans has been observed. Qualitative studies on migraine are needed in South Africa 
to determine its impact on the quality of life of patients.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 
PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN
Aguiar-Ibáñez R1, Gauthier A2, Umuhire D3, Johnston JA4, Zhao Y4, Le TK4
1i3 Innovus, Uxbridge, Middlesex, UK, 2Amaris, London, Middlesex, UK, 3i3 Innovus, 
Nanterre, France, 4Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Chronic low back pain (CLBP) is a major cause of disability, affecting 
mainly working-age adults and imposing a large economic burden on society. Since 
no consensus exists regarding standard of care for this condition, the objective of this 
study was to systematically review the efﬁcacy and safety of pharmacotherapies used 
for CLBP. METHODS: A systematic literature review was conducted through July/
August 2008, searching MEDLINE, EMBASE, and bibliographic details of relevant 
studies. Prospective trials and observational studies were included if they assessed 
pharmacotherapies in adults with CLBP and were written in English. Efﬁcacy end-
points included: pain relief, pain interference with activities, individual’s functioning 
and response to treatment. Adverse event (AE) rates and withdrawal rates due to AEs 
were also assessed. Extensive study heterogeneity prohibited quantitative synthesis. 
RESULTS: From 773 citations screened, 65 studies (published between 1982 and 
2008) were selected, of which 54 were randomized controlled trials. The efﬁcacy 
measures most consistently reported across studies included the visual analogue scale 
(VAS) and the Roland Morris Disability Questionnaire (RMDQ). Non-steroidal 
anti-inﬂammatory drugs (NSAIDs), weak and strong opioids, several antidepressants 
(clomipramine, mianserin, and duloxetine titrated based on patient response and toler-
ability), the anticonvulsant topiramate, and certain transdermal medications (trans-
dermal fentanyl and lidocaine patches) signiﬁcantly reduced pain intensity. The 
effectiveness of injections (i.e., glucose and lidocaine) and other antidepressants (par-
oxetine, trazodone or bupropion) was uncertain. Regarding patient functioning, sig-
niﬁcant improvements were observed for NSAIDs, opioids and duloxetine, but not for 
local injections. The magnitude of effect of these endpoints ranged from small to 
moderate, depending on the pharmacotherapy assessed. CONCLUSIONS: NSAIDs, 
opioids, some antidepressants, an anticonvulsant and certain transdermal medications 
seemed to signiﬁcantly reduce pain intensity in CLBP, while inconclusive results were 
obtained for other antidepressants and local injections. Overall, the study ﬁndings 
were consistent with current guideline recommendations from Europe and US.
PSY2
EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE: ARE 
THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER 
PATIENTS?
Bharmal M1, Garvert W2, Jo H2, Gemmen EK1, Hall JR3
1Quintiles, Inc, Falls Church, VA, USA, 2Quintiles, Inc., Falls Church, VA, USA, 3Quintiles, Inc., 
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OBJECTIVES: Propoxyphene is among the most commonly prescribed opioid anal-
gesic in the elderly. However, many guidelines, including the American Geriatric 
Society and Beer’s List of Potentially Inappropriate Medications, recommend restrict-
ing its use in that age group. These guidelines are based on expert opinions with limited 
empirical evidence. The objective of this study was to evaluate whether there were 
differences in adverse event reporting for propoxyphene by age group using a large 
post-marketing safety surveillance data. METHODS: Analysis was conducted using 
the 2005–2008 Adverse Event Reporting System (AERS) data in the US, which was 
developed to support the FDA’s post-marketing safety surveillance program for all 
approved products. Adverse events reported with propoxyphene as primary, second-
ary or interacting drug were categorized into central nervous system (CNS) and gas-
trointestinal (GI) adverse events (AEs). Logistic regressions were used to assess the 
risk of CNS and GI adverse events (AEs) among the elderly (age   65) and younger 
patients (age  65) controlling for gender and those reporting the AEs. Proportional 
reporting ratios (PRR) for the propoxyphene-AE combination were also computed for 
the elderly and younger patients. RESULTS: In the period 2005–2008, a total of 2497 
propoxyphene-AE combinations were reported, 261 were CNS-related and 127 were 
GI-related. In multivariate analysis, controlling for gender and those reporting the 
AEs, no signiﬁcant differences were observed in the risk of CNS-related AEs (Odds 
ratio: 0.827; 95% CI: 0.619–1.105; p  0.199) or GI-related AEs (Odds ratio: 1.216; 
95% CI: 0.832–1.778; p  0.313) among elderly versus young patients. Among the 
elderly, the PRR for propoxyphene-CNS AEs was 0.795 and the PRR for propoxy-
phene-GI AEs was 0.596. These were similar to the PRRs among younger patients, 
which were 0.700 and 0.439, respectively. CONCLUSIONS: Using a voluntary post-
marketing surveillance database, the study found no differences in the extent of CNS 
AEs and GI AEs reported with propoxyphene among elderly patients versus younger 
patients.
PSY3
DETERMINING THE COST OF OBESITY AND ITS MAJOR 
COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE
Padula WV, Nair KV
University of Colorado at Denver and the Health Sciences Center, Aurora, CO, USA
OBJECTIVES: To determine payments made by commercial health care providers for 
adults diagnosed with obesity, and those who are comorbid with any combination of 
the following chronic conditions: diabetes mellitus (DM), hypertension, depression, 
and/or congestive heart failure (CHF). METHODS: We utilized a 10% random sam-
pling from a commercial claims and encounters database (n  12,416,190). The study 
population (n  50,717) was limited to those who: 1) were adults age 18–64; 2) ﬁled 
a claim between 2006–2007; 3) had at least one inpatient visit, one outpatient visit, 
or one emergency department visit; and; 4) had been given a primary or secondary 
diagnosis of obesity. Persons were identiﬁed and categorized if they had one or more 
comorbid diagnoses (DM, hypertension, depression, and/or CHF) in addition to 
obesity. After adjusting for age and gender, we calculated the mean total net expen-
ditures (in $US 2007) for each combination of comorbid conditions. All calculations 
were performed in Stata. RESULTS: Among those diagnosed with obesity, the mean 
net expenditures for services were $1799 per patient. Persons diagnosed with obesity 
and other comorbidities observed an increase in total net expenditures. Obesity and 
hypertension observed the highest increase among single comorbidities at $4298. For 
persons with obesity and two other comorbidities, DM and depression was the highest 
at $14,364. The most expensive condition in the study sample was obesity, DM, 
hypertension and depression at $14,843. All results were statistically signiﬁcant at the 
95% conﬁdence level. CONCLUSIONS: Compared to the average medical claim, 
persons diagnosed with obesity along with other common chronic conditions experi-
ence signiﬁcant increases in health care costs. These costs are often driven higher by 
the time spent as inpatients. In many cases, obesity may be the cause of other chronic 
conditions that result in these high costs. Thus, by controlling and reducing the preva-
lence of obesity, we may see signiﬁcant decreases in health care expenditures.
PSY4
CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE 
OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT 
PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA
Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B
Erasmus MC, Rotterdam, The Netherlands
OBJECTIVES: Treatment of patients with acute myeloid leukemia (AML) is based 
upon stratiﬁcation into risk (prognosis) groups. New diagnostic methods are in devel-
opment to improve this stratiﬁcation. Economic evaluations of these methods require 
knowledge of what happens when the current stratiﬁcation methods are used. We 
examined whether the literature can provide valid estimates for the outcomes 
of complete remission rates for patients with primary AML aged 16–60 years. 
METHODS: A systematic literature review was performed using Pubmed and Embase. 
Inclusion criteria were: q100 AML patients and detailed outcomes per risk group 
(favorable, intermediate, unfavorable). Excluded were: Phase I/II studies, studies not 
containing any patients aged 16–60 years or with primary AML. We compared various 
study characteristics such as patient population, treatment given, risk group deﬁnitions 
and complete remission (CR) rates as outcome. A chi-square test for homogeneity of 
CR rates was performed. RESULTS: Twelve studies fulﬁlled the eligibility criteria. 
Great variation was found between study populations. While treatment varied between 
the studies, all patients received cytarabine and an anthracycline. Deﬁnitions of risk 
groups varied greatly except for the favorable risk group. There was no homogeneity 
in overall CR rate (range: 52–85% p  0.001). After excluding studies with many 
patients other than the target population, heterogeneity between the remaining studies 
decreased (N  7, p  0.083). CR rates were homogeneous in the favorable group (p 
 0.223), but heterogeneous in the intermediate and unfavorable groups (p  0.044 
and p  0.096 respectively). CONCLUSIONS: Differences in patient population and 
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risk group deﬁnitions lead to heterogeneity in CR rates. Only a small number of studies 
will provide valid estimates of the CR rates in patients with primary AML aged 16–60 
years. However, this restriction may reduce the reliability of the estimates, because 
the estimates will be based on fewer patients. This will thereby increase the uncertainty 
around the ICER of new methods.
PSY5
A RETROSPECTIVE CHART REVIEW OF THE TREATMENT OF 
PHENYLKETONURIA IN THE UK AND ASSOCIATED CLINICAL AND 
HEALTH OUTCOMES
Walters C1, Chauhan D1, Parkes L1, Chakrapani A2, MacDonald A2
1Merck Serono Ltd, Feltham, Middlesex, UK, 2Birmingham Children’s Hospital, Birmingham, 
UK
OBJECTIVES: To determine the proportion of phenylketonuria (PKU) patients 
managed successfully using current treatment strategies and to highlight a particular 
group(s) of PKU patients who may be uncontrolled by current treatment. METHODS: 
This is a non-interventional, retrospective, observational study. To date 4 UK sites 
have enrolled into the chart review. Information on patients with PKU or tetrahydro-
biopterin (BH4) deﬁciency was collected over a ﬁve year period (2004–2008). Data 
was collated on demographics, diagnosis, number of uncontrolled episodes, interven-
tions made during an uncontrolled episode and the length of time phenylalanine (Phe) 
levels were above the target level. An uncontrolled episode is deﬁned as three or more 
consecutive Phe levels above the National Society for Phenylketonuria (NSPKU) guide-
line. Interventions can include dietary advice, health care professional phone calls, 
clinic visits, counselling/psychological support, addition or change in use of supple-
ments, social care visits, and hospital admission. Data was analysed to explore the 
treatment of PKU in practice, the accompanying Phe levels and other health and clini-
cal outcomes. RESULTS: Recruitment is being completed. This information will be 
reported as a full dataset in the poster. Thus far data has been collected for 102 
patients across 3 centres (50% male). The age range of patients reviewed was 6–60 
years. A total of 93% of patients had a diagnosis of PKU, 0% BH4 deﬁciency and 
7% unknown. The average number of uncontrolled episodes per patient per year was 
1. An average of 7 interventions were made during each episode. The average length 
of the episode was 176 days. CONCLUSIONS: There is lack of published data on the 
management of PKU in clinical practice. This study provides an analysis of current 
treatment of PKU in clinical practice and its effectiveness on clinical and health out-
comes. The majority of PKU patients within this study had well-controlled Phe levels, 
however a number may beneﬁt from additional treatment.
PSY6
EFFECT OF MODERATE-INTENSITY EXERCISE TRAINING AND DIET ON 
BODY COMPOSITION AND EXERCISE CAPACITY IN OBESE CHILDREN
Tóth-Steinhausz V1, Gombocz K2, Lemle Z2, Stahl P2, Ferenczi A2, Bogáné Fatér Z1,  
Balog E1, Császárné Gombos G1, Kriszbacher I3, Schmidt B1
1University of Pécs, Zalaegerszeg, Hungary, 2Zala County Hospital, Zalaegerszeg, Hungary, 
3University of Pécs, Pécs, Hungary
OBJECTIVES: Childhood obesity is a serious health problem favouring the early 
development of insulin resistance, type-2 diabetes mellitus and cardiovascular diseases. 
Our aim was to investigate multidisciplinary weight-control program applying exercise 
training at maximal fat oxidation (FATmax) zone and diet in three different duration 
on body composition and physical ﬁtness of overweight children. METHODS: Thirty 
overweight pupils (BMI  percentile 90%) of three different elementary schools (age: 
11.7 / 1.9) was included. Body composition was determined by bioelectric imped-
ance method. Graded exercise test (Jaeger Oxycon Pro) was used to determine whole-
body peak fat oxidation by indirect calorimeter. Training heart rate interval was 
determined by as / 10% of FATmax. Physical exercises were prescribed by the 
physiotherapist. Exercise training was performed 2 times /week in the school using 
heart rate monitor under the control of the games master. The training periods were 
56, 101 and 146 days. Dietary proposal was given for the parents of children by the 
dietetics. RESULTS: At the end of the weight-control program percentage of fat mass 
decreased (35.7 / 4.5 vs. 33.0 / 5.5%; p  0.001), muscle mass increased (22.8 
/ 4.6 vs. 24.4 / 5.2 kg; p  0.001). VO2max increased at the longest training 
period only (1841 / 620 vs. 2011 / 642 ml; p  0.043). CONCLUSIONS: Moder-
ate intensity exercise training and diet resulted in favourable changes in the body 
composition in a short term whereas the signiﬁcant improvement of VO2max was 
started only after 5 months training period.
PSY7
EVALUATION OF MEASURES UNDERTAKEN TO ENHANCE THE 
ROBUSTNESS OF THE FABRY OUTCOME SURVEY (FOS)
Clarke J1, Beck M2, Giugliani R3, Sunder-Plassmann G4, Elliott P5, Hernberg-Stahl E6,  
Pintos-Morell G7
1Hospital for Sick Children, Toronto, Ontario, Canada, 2University of Mainz, Mainz, Germany, 
3Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, 4Medical University Vienna, Vienna, 
Austria, 5Heart Hospital, London, UK, 6Shire HGT AB, Danderyd, Sweden, 7University 
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OBJECTIVES: To assess the impact of measures undertaken to improve data capture 
in the Fabry Outcome Survey (FOS). A physician-directed, multinational database 
established in 2001, FOS aims to advance the understanding and management 
of Fabry disease, a rare lysosomal storage disorder caused by deﬁciency of alfa-
 galactosidase A. METHODS: This initiative, supported by Shire HGT is driven by 
physicians in the management of Fabry disease. In 2006, additional measures were 
introduced to enhance the robustness of data capture: 1) a core dataset was developed 
for assessing disease progression and therapy response; 2) focus was directed at those 
participating centers with q20 patients enrolled in FOS; and 3) research associates 
were employed to monitor data capture and quality. Random samples (25%) of all 
enrolled patients were selected from the years 2004 and 2007, before and after the 
changes, respectively. The completeness of data capture was determined for 10 core 
variables in each year. RESULTS: Data capture was analyzed for 197 of the 815 
patients enrolled in FOS in 2004 and for 404 of the 1616 patients enrolled in 2007. 
Increases in data capture occurred for 9 of 10 core variables; the exception was patient 
weights, which were unchanged at 90% for both years. For key variables, the increases 
were: signs and symptoms, from 66% to 83%; serum creatinine, from 89% to 91%; 
left ventricular mass, from 48% to 55%; NHYA score, from 84% to 87%. In addition, 
the proportion of females enrolled increased from 48% to 54%. CONCLUSIONS: 
Focused efforts on improving data completeness and quality in FOS have been 
 successful, optimizing the value of the database. Regular, accurate data collection 
and audit will increase the quality of FOS data and lead to an improved understanding 
of the management of Fabry disease.
PSY8
TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK 
PAIN: RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT 
FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES
Kavanagh S1, Lange B2, Ashworth J2, Etropolski MS3, McNeill M3, Rauschkolb C3
1Johnson & Johnson Pharmaceutical Services, Beerse, Belgium, 2Grünenthal GmbH, Aachen, 
Germany, 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, 
USA
OBJECTIVES: To evaluate the efﬁcacy and safety of tapentadol ER in patients with 
moderate-to-severe chronic low back pain. Health status was evaluated using SF-36 
and EQ-5D questionnaires. METHODS: Patients received controlled, adjustable 
twice-daily doses of tapentadol ER (100–250 mg), oxycodone HCl controlled release 
(CR; 20–50 mg), or placebo over a 12-week maintenance period, preceded by a 3-
week titration period. Patients completed the EQ-5D and SF-36 at baseline and at 
speciﬁed visits. EQ-5D evaluates mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression; SF-36 evaluates physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional, and mental health 
dimensions. RESULTS: Of 981 patients randomized, 958 were evaluated for efﬁcacy. 
Compared with placebo, improvements from baseline to endpoint in the SF-36 physi-
cal component summary score were signiﬁcantly greater with tapentadol ER (least-
squares mean difference vs placebo [95% CI], 2.3[1.02,3.58], P  0.001) and 
oxycodone CR (2.3[1.02,3.56], P  0.001). Both active treatment groups were associ-
ated with signiﬁcant improvements over placebo in role-physical (tapentadol ER, 
9.9[4.21,15.49]; oxycodone CR, 9.4[3.83,15.05]; both P  0.001) and bodily pain 
(tapentadol ER, 5.5[2.44,8.55]; oxycodone CR, 6.3[3.23,9.29]; both P  0.001). 
Additionally, tapentadol ER was associated with signiﬁcantly better outcomes versus 
placebo in physical functioning (4.1[0.85,7.33], P  0.013) and vitality (3.2[0.41,6.01], 
P  0.025), while oxycodone CR was not signiﬁcantly different from placebo on these 
parameters (physical functioning, 2.6[−0.66,5.77], P  0.119; vitality, 0.8[−1.99,3.58], 
P  0.576). For both active treatment groups, changes from baseline in general health, 
social functioning, role-emotional, mental health, and mental health summary score 
did not differ signiﬁcantly from placebo (all P  0.285). Compared with placebo, the 
EQ-5D health status index at endpoint improved signiﬁcantly compared with baseline 
with tapentadol ER (0.05[0.01,0.09], P  0.020) and oxycodone CR (0.05[0.01,0.09], 
P  0.019). Incidences of treatment-emergent adverse events were placebo, 59.6%; 
tapentadol ER, 75.5%; and oxycodone CR, 84.8%. CONCLUSIONS: Tapentadol ER 
(100–250 mg bid) signiﬁcantly improved physical and overall health status in patients 
with moderate-to-severe chronic low back pain.
PSY9
ADHERENCE TO DULOXETINE THERAPY AND HEALTH CARE COSTS 
AMONG PATIENTS WITH FIBROMYALGIA
Chen SY1, Boulanger L1, Fraser K1, Wu N1, Zhao Y2
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Eli Lilly and Company, Indianapolis, 
IN, USA
OBJECTIVES: To examine predictors of adherence to duloxetine therapy and assess 
the association between adherence and health care costs among working-age patients 
with ﬁbromyalgia. METHODS: This study analyzed medical and pharmacy records 
for commercially-insured patients aged 18–64 diagnosed with ﬁbromyalgia who initi-
ated duloxetine between January 1, 2006 and December 31, 2006. The date of ﬁrst 
duloxetine prescription ﬁlled was deﬁned as the index date. Initiation of treatment 
was deﬁned as no pill coverage for duloxetine over the prior 90 days. All patients 
included had at least 30 days supply of duloxetine in the 12 months post-index period. 
Patients with diabetes peripheral neuropathic pain or depression in the 12 months 
pre-index period were excluded. Two study cohorts were constructed based on adher-
ence level to duloxetine (high adherence  medication possession ratio of  0.8). Pre-
dictors of high adherence were examined via logistic regression. Multivariate regression 
models were performed to examine the association between adherence and health care 
costs, controlling for demographics, clinical characteristics, and prior health care costs. 
RESULTS: A total of 4869 ﬁbromyalgia patients were identiﬁed, with a mean age of 
50 years and 88% female. Approximately 68% of duloxetine patients had low adher-
ence over the 12 months follow-up period. Higher average daily dose was associated 
with high adherence (reference group  30 mg; Odds Ratio  3.03, 2.40, and 3.74 for 
31–59 mg, 60 mg, and  60 mg, respectively; all p  0.05). Controlling for differences 
